India, Sept. 8 -- Mankind Pharma on Monday announced that it has obtained approval from the Central Drugs Standard Control Organisation (CDSCO) to commence Phase 1 clinical trials for a molecule aimed at treating multiple autoimmune disorders.
The molecule, MKP11093, is being developed for conditions including rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia. Developed at the Mankind Research Centre, the drug demonstrated promising safety and selectivity in preclinical studies, the company said.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....